Identification and Development of BRD9 Chemical Probes
The development of BRD9 inhibitors involves the design and synthesis of molecules that can specifically bind the BRD9 protein, interfering with the function of the chromatin-remodeling complex ncBAF, with the main advantage of modulating gene expression and controlling cellular processes. Here, we s...
Main Authors: | Ester Colarusso, Maria Giovanna Chini, Giuseppe Bifulco, Gianluigi Lauro, Assunta Giordano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/17/3/392 |
Similar Items
-
Insights into the Ligand Binding to Bromodomain-Containing Protein 9 (BRD9): A Guide to the Selection of Potential Binders by Computational Methods
by: Simona De Vita, et al.
Published: (2021-11-01) -
MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma
by: Gen Li, et al.
Published: (2024-02-01) -
A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells
by: Kunlong Zhang, et al.
Published: (2022-06-01) -
Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells
by: Qiang Wang, et al.
Published: (2023-01-01) -
Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles
by: Yihong He, et al.
Published: (2022-12-01)